Twist Bioscience Corporation (NASDAQ:TWST) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have been given an average rating of “Moderate Buy” by the ten brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $71.60.

Several equities analysts have recently commented on TWST shares. Leerink Partners set a $80.00 target price on Twist Bioscience in a research note on Friday, May 22nd. Barclays increased their target price on Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Canaccord Genuity Group initiated coverage on Twist Bioscience in a research note on Monday, June 15th. They set a “buy” rating and a $90.00 price objective on the stock. Piper Sandler initiated coverage on Twist Bioscience in a research note on Thursday, June 11th. They set an “overweight” rating and a $85.00 price objective on the stock. Finally, Robert W. Baird raised their price objective on Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th.

Insider Activity

In related news, insider Dennis Cho sold 402 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $69.84, for a total transaction of $28,075.68. Following the transaction, the insider directly owned 119,692 shares in the company, valued at $8,359,289.28. This trade represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 4,000 shares of the firm’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $60.00, for a total value of $240,000.00. Following the transaction, the chief financial officer owned 118,694 shares in the company, valued at $7,121,640. This trade represents a 3.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 33,170 shares of company stock valued at $1,948,964 over the last three months. 3.08% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Large investors have recently added to or reduced their stakes in the company. Western Wealth Management LLC bought a new position in Twist Bioscience during the first quarter worth $31,000. Strs Ohio bought a new position in Twist Bioscience during the first quarter worth $33,000. PNC Financial Services Group Inc. lifted its stake in Twist Bioscience by 89.7% during the first quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after purchasing an additional 453 shares during the last quarter. Quarry LP acquired a new stake in Twist Bioscience in the third quarter worth $28,000. Finally, Strategic Advocates LLC increased its position in Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after buying an additional 906 shares during the period.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $85.00 on Wednesday. The stock has a market cap of $5.29 billion, a P/E ratio of -63.91 and a beta of 2.23. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. The stock has a 50 day moving average of $64.56 and a 200-day moving average of $50.23. Twist Bioscience has a 52 week low of $23.30 and a 52 week high of $89.71.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The business had revenue of $110.72 million for the quarter, compared to analysts’ expectations of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.66) earnings per share. On average, analysts expect that Twist Bioscience will post -2.02 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.